Loading…

Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature

Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, bu...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2022-11, Vol.39 (6), p.960-966
Main Authors: Mistry, Bhavik Dipak, Leis, Maria, Lee, David Michael, Levy, Rebecca
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3
cites cdi_FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3
container_end_page 966
container_issue 6
container_start_page 960
container_title Pediatric dermatology
container_volume 39
creator Mistry, Bhavik Dipak
Leis, Maria
Lee, David Michael
Levy, Rebecca
description Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.
doi_str_mv 10.1111/pde.15095
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2694417867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2740453928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EEqWw4A8ssYFFWjt24oRdVcpDAsEC1pbjTFpXeWE7Lf17XMoKidnMHenM1cxF6JKSCQ017UuY0ITkyREa0SROIsoFOUYjIlgaZYSnp-jMuTUhJEtTOkLwolq1hAZaj7sK91Aa5a3RQTX9yiwHhzdDvVTWOLw1foWt8cOXaVRxi2dYKwfYQt9Zj1VbBrkxsN0b-RXg2niwyg8WztFJpWoHF799jD7uF-_zx-j59eFpPnuONGMkieKSVHFelYJnldZcUVEIofKcZSyHoig1LQsq8jAAi3XGQHCelYoWjKYxUM3G6Prg29vucwDnZWOchrpWLXSDk3Gac05FloqAXv1B191g23CdjAUnPGF5nAXq5kBp2zlnoZK9Dc_bnaRE7gOXIXD5E3hgpwd2a2rY_Q_Kt7vFYeMbzkSCag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2740453928</pqid></control><display><type>article</type><title>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</title><source>Wiley</source><creator>Mistry, Bhavik Dipak ; Leis, Maria ; Lee, David Michael ; Levy, Rebecca</creator><creatorcontrib>Mistry, Bhavik Dipak ; Leis, Maria ; Lee, David Michael ; Levy, Rebecca</creatorcontrib><description>Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.15095</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>Autoantibodies ; Autoimmune diseases ; Bullous diseases ; Case reports ; CD20 antigen ; Corticosteroids ; Immunoglobulin G ; Immunotherapy ; Literature reviews ; management ; Monoclonal antibodies ; pediatric pemphigus vulgaris ; Pediatrics ; Pemphigus ; Rituximab ; Skin diseases ; topical corticosteroids ; treatment</subject><ispartof>Pediatric dermatology, 2022-11, Vol.39 (6), p.960-966</ispartof><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</citedby><cites>FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</cites><orcidid>0000-0001-7284-3128</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Mistry, Bhavik Dipak</creatorcontrib><creatorcontrib>Leis, Maria</creatorcontrib><creatorcontrib>Lee, David Michael</creatorcontrib><creatorcontrib>Levy, Rebecca</creatorcontrib><title>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</title><title>Pediatric dermatology</title><description>Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.</description><subject>Autoantibodies</subject><subject>Autoimmune diseases</subject><subject>Bullous diseases</subject><subject>Case reports</subject><subject>CD20 antigen</subject><subject>Corticosteroids</subject><subject>Immunoglobulin G</subject><subject>Immunotherapy</subject><subject>Literature reviews</subject><subject>management</subject><subject>Monoclonal antibodies</subject><subject>pediatric pemphigus vulgaris</subject><subject>Pediatrics</subject><subject>Pemphigus</subject><subject>Rituximab</subject><subject>Skin diseases</subject><subject>topical corticosteroids</subject><subject>treatment</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kMtOwzAQRS0EEqWw4A8ssYFFWjt24oRdVcpDAsEC1pbjTFpXeWE7Lf17XMoKidnMHenM1cxF6JKSCQ017UuY0ITkyREa0SROIsoFOUYjIlgaZYSnp-jMuTUhJEtTOkLwolq1hAZaj7sK91Aa5a3RQTX9yiwHhzdDvVTWOLw1foWt8cOXaVRxi2dYKwfYQt9Zj1VbBrkxsN0b-RXg2niwyg8WztFJpWoHF799jD7uF-_zx-j59eFpPnuONGMkieKSVHFelYJnldZcUVEIofKcZSyHoig1LQsq8jAAi3XGQHCelYoWjKYxUM3G6Prg29vucwDnZWOchrpWLXSDk3Gac05FloqAXv1B191g23CdjAUnPGF5nAXq5kBp2zlnoZK9Dc_bnaRE7gOXIXD5E3hgpwd2a2rY_Q_Kt7vFYeMbzkSCag</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Mistry, Bhavik Dipak</creator><creator>Leis, Maria</creator><creator>Lee, David Michael</creator><creator>Levy, Rebecca</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7284-3128</orcidid></search><sort><creationdate>202211</creationdate><title>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</title><author>Mistry, Bhavik Dipak ; Leis, Maria ; Lee, David Michael ; Levy, Rebecca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Autoantibodies</topic><topic>Autoimmune diseases</topic><topic>Bullous diseases</topic><topic>Case reports</topic><topic>CD20 antigen</topic><topic>Corticosteroids</topic><topic>Immunoglobulin G</topic><topic>Immunotherapy</topic><topic>Literature reviews</topic><topic>management</topic><topic>Monoclonal antibodies</topic><topic>pediatric pemphigus vulgaris</topic><topic>Pediatrics</topic><topic>Pemphigus</topic><topic>Rituximab</topic><topic>Skin diseases</topic><topic>topical corticosteroids</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mistry, Bhavik Dipak</creatorcontrib><creatorcontrib>Leis, Maria</creatorcontrib><creatorcontrib>Lee, David Michael</creatorcontrib><creatorcontrib>Levy, Rebecca</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mistry, Bhavik Dipak</au><au>Leis, Maria</au><au>Lee, David Michael</au><au>Levy, Rebecca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</atitle><jtitle>Pediatric dermatology</jtitle><date>2022-11</date><risdate>2022</risdate><volume>39</volume><issue>6</issue><spage>960</spage><epage>966</epage><pages>960-966</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/pde.15095</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7284-3128</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0736-8046
ispartof Pediatric dermatology, 2022-11, Vol.39 (6), p.960-966
issn 0736-8046
1525-1470
language eng
recordid cdi_proquest_miscellaneous_2694417867
source Wiley
subjects Autoantibodies
Autoimmune diseases
Bullous diseases
Case reports
CD20 antigen
Corticosteroids
Immunoglobulin G
Immunotherapy
Literature reviews
management
Monoclonal antibodies
pediatric pemphigus vulgaris
Pediatrics
Pemphigus
Rituximab
Skin diseases
topical corticosteroids
treatment
title Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A20%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20pediatric%20pemphigus%20vulgaris%20with%20rituximab:%20A%20case%20report%20and%20review%20of%20the%20literature&rft.jtitle=Pediatric%20dermatology&rft.au=Mistry,%20Bhavik%20Dipak&rft.date=2022-11&rft.volume=39&rft.issue=6&rft.spage=960&rft.epage=966&rft.pages=960-966&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.15095&rft_dat=%3Cproquest_cross%3E2740453928%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2740453928&rft_id=info:pmid/&rfr_iscdi=true